Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
FENSOLVI for injectable suspension is a sterile polymeric matrix formulation of leuprolide acetate, a GnRH agonist, for subcutaneous use. It is designed to deliver leuprolide acetate at a controlled rate over a six-month therapeutic period.
Leuprolide acetate is a synthetic nonapeptide analog of naturally occurring gonadotropin releasing hormone. The analog possesses greater potency than the natural hormone. The chemical name is 5-oxo-Lprolyl- L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide acetate (salt) with the following structural formula:
 |
FENSOLVI is prefilled and supplied in two separate, sterile syringes whose contents are mixed immediately prior to administration. The two syringes are joined and the single dose product is mixed until it is homogenous. FENSOLVI is administered subcutaneously, where it forms a solid drug delivery depot.
One syringe contains the ATRIGEL Delivery System and the other contains the leuprolide acetate. ATRIGEL is a polymeric (non-gelatin containing) delivery system consisting of a biodegradable poly(DL-lactide-coglycolide) (PLG) polymer formulation dissolved in the biocompatible solvent, N-methyl-2-pyrrolidone (NMP).
Refer to Table 3 for the delivery system composition and reconstituted product formulation for FENSOLVI product.
Table 3: FENSOLVI Delivery System Composition and Reconstituted Product Formulation
| ATRIGEL Delivery System Syringe | Polymer | PLG |
| Polymer description | Copolymer with hexanediol | |
| Polymer DL-lactide to glycolide molar ratio | 85:15 | |
| Reconstituted Product | Polymer delivered | 165 mg |
| NMP delivered | 165 mg | |
| Leuprolide acetate delivered | 45 mg | |
| Approximate leuprolide free base equivalent | 42 mg | |
| Approximate administered formulation weight | 375 mg | |
| Approximate injection volume | 0.375 mL |
FENSOLVI® is indicated for the treatment of pediatric patients 2 years of age and older with central precocious puberty (CPP).
FENSOLVI must be administered by a healthcare provider.
The dose of FENSOLVI is 45 mg administered by subcutaneous injection once every six months.
Discontinue FENSOLVI treatment at the appropriate age of onset of puberty.
Monitor response to FENSOLVI with a GnRH agonist stimulation test, basal serum luteinizing hormone (LH) levels or serum concentration of sex steroid levels at 1 to 2 months following initiation of therapy and as needed to confirm adequate suppression of pituitary gonadotropins, sex steroids, and progression of secondary sexual characteristics. Measure height (for calculation of growth velocity) every 3 to 6 months and monitor bone age periodically.
Noncompliance with drug regimen or inadequate dosing may lead to gonadotropins and/or sex steroids increasing above prepubertal levels resulting in inadequate control of the pubertal process. If the dose of FENSOLVI is not adequate, switching to an alternative GnRH agonist for the treatment of CPP with the ability for dose adjustment may be necessary.
Use aseptic technique including gloves for reconstitution and administration. Allow the product to reach room temperature before reconstitution to allow for easier administration. Once reconstituted, the concentration is 45 mg/0.375 mL. Administer the product within 30 minutes or discard.
FENSOLVI is packaged in a carton containing:
Follow the detailed instructions below to ensure correct preparation of FENSOLVI prior to administration:
On a clean field open the tray by tearing off the foil from the corner and remove the contents. Discard the desiccant pack. Remove the pre-connected syringe system from the tray. Open the sterile safety needle package by peeling back the paper tab. Note: Syringe A and Syringe B should not be lined-up yet. The product should only be administered with the co-packaged, sterile safety needle.
 |
 |
Grasp the latching button on the coupling device with your finger and thumb and press until you hear a snapping sound. The two syringes will be aligned.
Do not bend the pre-connected syringe system.
 |
Holding the syringes in a horizontal position, transfer the liquid contents of Syringe A into the leuprolide acetate powder contained in Syringe B.Thoroughly mix the product for 60 cycles by pushing the contents back and forth between both syringes to obtain a uniform suspension.
Note: Product must be mixed as described; shaking will NOT provide adequate mixing. Do not bend.
 |
After mixing, hold the syringes vertically (upright) with Syringe B (wide syringe) on the bottom. The syringes should remain securely coupled.
Transfer all of the mixed product into Syringe B by depressing the Syringe A plunger and slightly withdrawing the Syringe B plunger.
 |
While ensuring the Syringe A plunger is fully pushed down, hold the coupling device and unscrew Syringe B. This will disconnect Syringe B from the coupling device. Syringe A will remain attached to the coupling device.
Note: Small air bubbles will remain in the formulation – this is acceptable.
Do not purge the air bubbles from Syringe B as product may be lost!
 |
Continue to hold Syringe B upright with the open end at the top. Hold back the white plunger on Syringe B to prevent loss of the product and attach the safety needle and cap. Gently screw clockwise with approximately a threequarter turn until the safety needle and cap are secure.
Do not overtighten, as the needle hub may become damaged which could result in leakage of the product during injection The safety shield may also be damaged if the safety needle and cap are screwed with too much force.
 |
Move the safety shield away from the needle and towards the syringe. Pull off the cap immediately prior to administration.
Note: Should the needle hub appear to be damaged, or leak, do not use the product. If the needle hub is damaged or leakage is observed, use a new FENSOLVI carton.
 |
 |
 |
 |
For injectable suspension, 45 mg of leuprolide acetate.
Each FENSOLVI carton contains:
For injectable suspension, 45 mg of leuprolide acetate (NDC 62935-163-60) supplied in a carton that contains:
Store refrigerated at 2°C to 8°C (36°F to 46°F).
Once outside the refrigerator, this product may be stored in its original packaging at room temperature 15°C to 30°C (59°F to 86°F) for up to eight weeks prior to reconstitution and administration.
Manufactured by: Tolmar, Fort Collins, CO 80526 04006226. Revised: Apr 2023
The following serious adverse reactions are described here and elsewhere in the label:
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
FENSOLVI was evaluated in an uncontrolled, open-label, single-arm clinical trial in which 64 pediatric patients with CPP received at least one dose of FENSOLVI. The age ranged from 4 to 9 years at start of treatment; 62 patients were female and 2 were male; 53% White; 23% Black; 8% American Indian or Alaska Native; 5% Asian; 2% Native Hawaiian or Other Pacific Islander. 56% of the subjects self-identified as Hispanic or Latino ethnicity. Adverse reactions that occurred in ≥ 5% of patients are shown in Table 1.
Table 1: Adverse Reactions Occurring in ≥ 5% of Patients Treated with FENSOLVI in an Open-Label, Single-Arm Trial
| Adverse Reactions | % of Patients (N=64) |
| Injection site pain | 31 |
| Nasopharyngitis | 22 |
| Pyrexia | 17 |
| Headache | 16 |
| Cough | 13 |
| Abdominal pain | 9 |
| Injection site erythema | 9 |
| Nausea | 8 |
| Constipation | 6 |
| Vomiting | 6 |
| Upper respiratory tract infection | 6 |
| Bronchospasm | 6 |
| Productive cough | 6 |
| Hot flush | 5 |
Psychiatric
Emotional disorder (2%) and irritability (2%)
The following adverse reactions have been identified during postapproval use of leuprolide acetate or FENSOLVI. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Allergic Reactions: anaphylactic, rash, urticaria, and photosensitivity reactions.
General: chest pain, weight increase, weight decrease, decreased appetite, fatigue.
Laboratory Abnormalities: decreased WBC.
Metabolic: diabetes mellitus.
Musculoskeletal and Connective Tissue: arthralgia, epiphysiolysis, muscle spasms, myalgia.
Neurologic: neuropathy peripheral, convulsion, paralysis, insomnia, pseudotumor cerebri (idiopathic intracranial hypertension).
Psychiatric: emotional lability, such as crying, irritability, impatience, anger and aggression, depression, including rare reports of suicidal ideation and attempt. Many, but not all, of these patients had a history of psychiatric illness or other comorbidities with an increased risk of depression.
Skin and Subcutaneous Tissue: injection site reactions including induration and abscess, flushing, hyperhidrosis.
Reproductive System: vaginal bleeding, breast enlargement.
Vascular: hypertension, hypotension.
Respiratory: dyspnea.
No Information Provided
Included as part of the "PRECAUTIONS" Section
During the early phase of therapy, gonadotropins and sex steroids rise above baseline because of the initial stimulatory effect of the drug [see CLINICAL PHARMACOLOGY]. Therefore, an increase in clinical signs and symptoms of puberty including vaginal bleeding may be observed during the first weeks of therapy or after subsequent doses [see ADVERSE REACTIONS]. Instruct patients and caregivers to notify the physician if these symptoms continue beyond the second month after FENSOLVI administration.
Psychiatric events have been reported in patients taking GnRH agonists, including leuprolide acetate. Postmarketing reports with this class of drugs include symptoms of emotional lability, such as crying, irritability, impatience, anger, and aggression. Monitor for development or worsening of psychiatric symptoms during treatment with FENSOLVI [see ADVERSE REACTIONS].
Postmarketing reports of convulsions have been observed in patients receiving GnRH agonists, including leuprolide acetate. These included patients with a history of seizures, epilepsy, cerebrovascular disorders, central nervous system anomalies or tumors, and patients on concomitant medications that have been associated with convulsions such as bupropion and SSRIs. Convulsions have also been reported in patients in the absence of any of the conditions mentioned above [see ADVERSE REACTIONS].
Pseudotumor cerebri (idiopathic intracranial hypertension) have been reported in pediatric patients receiving GnRH agonists, including leuprolide acetate. Monitor patients for signs and symptoms of pseudotumor cerebri, including headache, papilledema, blurred vision, diplopia, loss of vision, pain behind the eye or pain with eye movement, tinnitus, dizziness, and nausea [see ADVERSE REACTIONS].
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Inform patients and caregivers that during the early phase of therapy with FENSOLVI, gonadotropins and sex steroids rise above baseline because of the initial stimulatory effect of the drug. Therefore, an increase in clinical signs and symptoms of puberty may be observed. Instruct patients and caregivers to notify the physician if these symptoms continue beyond the second month after FENSOLVI administration [see WARNINGS AND PRECAUTIONS].
Inform patients and caregivers that psychiatric events have been reported in patients taking GnRH agonists, including leuprolide acetate. Events include emotional lability, such as crying, irritability, impatience, anger, and aggression. Instruct patients and caregivers to monitor for development or worsening of psychiatric symptoms including depression during treatment with FENSOLVI [see WARNINGS AND PRECAUTIONS].
Inform patients and caregivers that reports of convulsions have been observed in patients receiving GnRH agonists, including leuprolide acetate. Patients with a history of seizures, epilepsy, cerebrovascular disorders, central nervous system anomalies or tumors, and patients on concomitant medications that have been associated with convulsions may be at increased risk [see WARNINGS AND PRECAUTIONS].
Inform patients and caregivers that reports of pseudotumor cerebri (idiopathic intracranial hypertension) have been observed in pediatric patients receiving GnRH agonists, including leuprolide acetate. Advise patients and caregivers to monitor for headache, and vision issues such as blurred vision, double vision, loss of vision, pain behind the eye or pain with eye movement, ringing in the ears, dizziness, and nausea. Advise patients and caregivers to contact their healthcare provider if the patient develops any these symptoms. [see WARNINGS AND PRECAUTIONS].
Inform patients and caregivers that injection site related adverse reactions may occur such as transient burning/stinging, pain, bruising, and redness. Advise patients to contact their healthcare provider if they experience rash or severe injection site reactions [see ADVERSE REACTIONS].
FENSOLVI is contraindicated in pregnancy. If the patient becomes pregnant while taking the drug, the patient should be informed of the potential risk to the fetus [see Use In Specific Populations].
Inform caregivers about the importance of adherence to the FENSOLVI dosing schedule of one injection every 24 weeks [see DOSAGE AND ADMINISTRATION].
Two-year carcinogenicity studies were conducted with leuprolide acetate in rats and mice. In rats, a dose-related increase of benign pituitary hyperplasia and benign pituitary adenomas was noted at 24 months when the drug was administered subcutaneously at high daily doses (0.6 to 4 mg/kg). There was a significant but not dose-related increase of pancreatic islet-cell adenomas in females and of testicular interstitial cell adenomas in males (highest incidence in the low dose group). In mice, no leuprolide acetate-induced tumors or pituitary abnormalities were observed at a dose as high as 60 mg/kg for two years. Patients have been treated with leuprolide acetate for up to three years with doses as high as 10 mg/day and for two years with doses as high as 20 mg/day without demonstrable pituitary abnormalities. No carcinogenicity studies have been conducted with FENSOLVI.
Mutagenicity studies have been performed with leuprolide acetate using bacterial and mammalian systems. These studies provided no evidence of a mutagenic potential.
FENSOLVI is contraindicated in pregnancy [see CONTRAINDICATIONS].
FENSOLVI may cause fetal harm based on findings from animal studies and the drug’s mechanism of action [see CLINICAL PHARMACOLOGY]. The available data from published clinical studies and case reports and from the pharmacovigilance database on exposure to leuprolide acetate during pregnancy are insufficient to assess the risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Based on animal reproduction studies, leuprolide acetate may be associated with an increased risk of pregnancy complications, including early pregnancy loss and fetal harm. In animal reproduction studies, subcutaneous administration of leuprolide acetate to rabbits during the period of organogenesis caused embryo-fetal toxicity, decreased fetal weights and a dose-dependent increase in major fetal abnormalities in animals at doses less than the recommended human dose based on body surface area using an estimated daily dose. A similar rat study also showed increased fetal mortality and decreased fetal weights but no major fetal abnormalities at doses less than the recommended human dose based on body surface area using an estimated daily dose (see Data).
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Animal Data
When administered on day 6 of pregnancy at test dosages of 0.00024 mg/kg, 0.0024 mg/kg, and 0.024 mg/kg (1/3255 to 1/33 of the human dose) to rabbits, leuprolide acetate produced a dose-related increase in major fetal abnormalities. Similar studies in rats failed to demonstrate an increase in fetal malformations. There was increased fetal mortality and decreased fetal weights with the two higher doses of leuprolide acetate in rabbits and with the highest dose (0.024 mg/kg) in rats.
There are no data on the presence of leuprolide acetate in either animal or human milk, the effects on the breastfed infants, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for FENSOLVI and any potential adverse reactions on the breastfed infant from FENSOLVI or from the underlying maternal condition.
Exclude pregnancy in women of reproductive potential prior to initiating FENSOLVI if clinically indicated [see Pregnancy].
Females
FENSOLVI may cause embryo-fetal harm when administered during pregnancy
FENSOLVI is not a contraceptive. If contraception is indicated, advise females of reproductive potential to use a non-hormonal method of contraception during treatment with FENSOLVI [see Pregnancy].
Based on its pharmacodynamic effects of decreasing secretion of gonadal steroids, fertility is expected to be decreased while on treatment with FENSOLVI. Clinical and pharmacologic studies in adults (>18 years) with leuprolide acetate and similar analogs have shown reversibility of fertility suppression when the drug is discontinued after continuous administration for periods of up to 24 weeks [see CLINICAL PHARMACOLOGY].
There is no evidence that pregnancy rates are affected following discontinuation of FENSOLVI.
Animal studies (prepubertal and adult rats and monkeys) with leuprolide acetate and other GnRH analogs have shown functional recovery of fertility suppression.
The safety and effectiveness of FENSOLVI for the treatment of CPP has been established in pediatric patients 2 years of age and older. Use of FENSOLVI for this indication is supported by evidence from an adequate and uncontrolled open-label, single-arm study of 64 pediatric patients with CPP with an age range of 4 to 9 years [see Clinical Studies]. The safety and effectiveness of FENSOLVI have not been established in pediatric patients less than 2 years old.
No specific antidotes for FENSOLVI are known. Contact Poison Control (1-800-222- 1222) for latest recommendations.
Leuprolide acetate, a GnRH agonist, acts as a potent inhibitor of gonadotropin secretion (LH and follicle stimulating hormone (FSH)) when given continuously in therapeutic doses. Following an initial stimulation of GnRH receptors, chronic administration of leuprolide acetate results in downregulation of GnRH receptors, reduction in release of LH, FSH and consequent suppression of ovarian and testicular production of estradiol and testosterone respectively. This inhibitory effect is reversible upon discontinuation of drug therapy.
In the clinical trial evaluating FENSOLVI in pediatric patients with CPP, there was a transient surge in circulating levels of LH, FSH, estradiol and testosterone following the first administration. A decrease in basal and GnRH agonist-stimulated LH and FSH levels along with reductions in basal estradiol and testosterone were observed after repeat administration.
After an initial subcutaneous injection of FENSOLVI 45 mg in pediatric patients 4 to 9 years of age with CPP, leuprolide levels peaked 4 hours postdose with a mean C of 212.3 ng/mL. Absorption occurred in two phases, a burst phase followed by a plateau phase. The mean plateau serum leuprolide level from 4 to 48 weeks was approximately 0.37 ng/mL with a range of 0.18 to 0.63 ng/mL. There was no accumulation of leuprolide after the second dose.
The distribution of leuprolide following FENSOLVI administration was not evaluated in pediatric patients. The mean steady-state volume of distribution of leuprolide following intravenous bolus administration to healthy male volunteers was 27 L.
In vitro binding of leuprolide to human plasma proteins ranged from 43% to 49%.
Metabolism
In rats and dogs, administration of 14C-labeled leuprolide was shown to be metabolized to smaller inactive peptides: a pentapeptide (Metabolite I), tripeptides (Metabolites II and III), and a dipeptide (Metabolite IV). These fragments may be further catabolized.
In healthy male volunteers, a 1 mg bolus of leuprolide administered intravenously revealed that the mean systemic clearance was 8.34 L/h, with a terminal elimination halflife of approximately 3 hours based on a two-compartment model.
Upon administration with different leuprolide acetate formulations, the major metabolite of leuprolide acetate is a pentapeptide (M-1) metabolite.
The pharmacokinetics of FENSOLVI in hepatically and renally impaired pediatric patients have not been determined.
The efficacy of FENSOLVI was evaluated in an uncontrolled, open-label, single arm clinical trial in which 64 pediatric patients (62 females and 2 males, naïve to previous GnRH agonist treatment) with CPP received at least one dose of FENSOLVI at a dosing interval of 24 weeks and were observed for 12 months. The mean age was 7.5 years (range 4 to 9 years) at the start of treatment. In pediatric patients with CPP, FENSOLVI reduced stimulated and basal gonadotropins to prepubertal levels. Suppression of peak stimulated LH concentrations to <4 IU/L was achieved in 87% of pediatric patients by month 6 and in 86% of patients by month 12. Suppression of estradiol or testosterone concentration to prepubertal levels at the 6-month assessment was achieved in 97% and 100% of patients, respectively. Suppression of estradiol or testosterone was maintained at the 12-month assessment with 98% (55/56 females) and 50% (1/2 males) maintaining suppression. FENSOLVI arrested or reversed progression of clinical signs of puberty with reductions in growth velocity and bone age. Mean growth velocity decreased from 8.9 ± 13.1 cm/yr at 1 month to 6.9 ± 3.1 cm/yr at 6 months and to 6.4 ± 1.9 cm/yr at 12 months.
Table 3: Reproductive Hormone Levels in Pediatric Patients with CPP Treated with FENSOLVI 45 mg Every 6 Monthsa
| Endpointb | % (n/N) of Patients Achieving Endpoints | |||
| Month 3 |
Month 6 |
Month 9 |
Month 12 |
|
| LH levels < 4 IU/L | 85 (51/60) |
87 (54/62)c |
85 (50/59) |
86 (50/58) |
| Estradiol levels < 73.4 pmol/L (< 20 pg/mL) | 98 (56/57) |
97 (58/60) |
98 (56/57) |
98 (55/56) |
| Testosterone levels < 1 nmol/L (< 28.4 ng/dL) | 100 (2/2) |
100 (2/2) |
100 (2/2) |
50 (1/2) |
| FSH levels < 2.5 IU/L | 62 (37/60) |
66 (41/62) |
44 (26/59) |
55(32/58) |
| aIntent-to-treat Population (N=62) bPost GnRH agonist stimulation cPrimary Efficacy Endpoint |
||||
Eight female patients out of 62 did not meet the primary efficacy criteria for LH <4 IU/L at 6 months. In four of the eight patients, the LH level at 6 months was between 4.2 and 4.8 IU/L. The remaining four patients had LH levels >5 IU/L. However, post stimulation estradiol was suppressed to prepubertal levels (<20 pg/mL) in seven of the eight patients at month 6 and was maintained through month 12.
FENSOLVI®
(fen-SOL-vee)
(leuprolide acetate) injectable suspension, for subcutaneous use
What is the most important information I should know about FENSOLVI?
FENSOLVI may cause serious side effects, including:
Call your child’s healthcare provider right away if your child has any new or worsening emotional symptoms while taking FENSOLVI.
Seizures have also happened in people who have not had any of these problems.
Call your child’s healthcare provider right away if your child has a seizure while taking FENSOLVI.
What is FENSOLVI?
FENSOLVI should not be received if your child is:
Call your child’s healthcare provider or get emergency medical help right away if your child gets any of the following symptoms of a serious allergic reaction:
Before your child receives FENSOLVI, tell your child’s healthcare provider about all of your child’s medical conditions, including if they:
Tell your healthcare provider about all the medicines your child takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How will your child receive FENSOLVI?
What are the possible side effects of FENSOLVI?
FENSOLVI may cause serious side effects. See “What is the most important information I should know about FENSOLVI?”
The most common side effects of FENSOLVI include:
These are not all the possible side effects of FENSOLVI. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA- 1088.
General information about the safe and effective use of FENSOLVI.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide.
You can ask your pharmacist or healthcare provider for information about FENSOLVI that is written for health professionals.
What are the ingredients in FENSOLVI?
Active ingredient: leuprolide acetate.
Inactive ingredients: poly (DL-lactide-co-glycolide) and N-methyl-2-pyrrolidone.
This Medication Guide has been approved by the U.S. Food and Drug Administration
INSTRUCTIONS FOR USE
Follow the detailed instructions below to ensure correct preparation of Fensolvi prior to administration:
Step 1
Use aseptic technique including gloves for reconstitution and administration. Allow the product to reach room temperature before reconstitution to allow for easier administration. Administer the product within 30 minutes or discard.
On a clean field open the tray by tearing off the foil from the corner and remove the contents. Discard the desiccant pack. Remove the pre-connected syringe system from the tray. Open the sterile safety needle package by peeling back the paper tab. Note: Syringe A and Syringe B should not be lined-up yet. The product should only be administered with the co-packaged, sterile safety needle.
 |
 |
Step 2
Grasp the latching button on the coupling device with your finger and thumb and press until you hear a snapping sound. The two syringes will be aligned.
Do not bend the pre-connected syringe system.
 |
Step 3
Holding the syringes in a horizontal position, transfer the liquid contents of Syringe A into the leuprolide acetate powder contained in Syringe B. Thoroughly mix the product for 60 cycles by pushing the contents back and forth between both syringes to obtain a uniform suspension.
Note: Product must be mixed as described; shaking will NOT provide adequate mixing. Do not bend.
 |
Step 4
After mixing, hold the syringes vertically (upright) with Syringe B (wide syringe) on the bottom. The syringes should remain securely coupled.
Transfer all of the mixed product into Syringe B by depressing the Syringe A plunger and slightly withdrawing the Syringe B plunger.
 |
Step 5
While ensuring the Syringe A plunger is fully pushed down, hold the coupling device and unscrew Syringe B. This will disconnect Syringe B from the coupling device. Syringe A will remain attached to the coupling device.
Note: Small air bubbles will remain in the formulation – this is acceptable.
Do not purge the air bubbles from Syringe B as product may be lost!
 |
Step 6
Continue to hold Syringe B upright with the open end at the top. Hold back the white plunger on Syringe B to prevent loss of the product and attach the the white plunger on Syringe B to prevent loss of the product and attach the safety needle and cap. Gently screw clockwise with approximately a threequarter turn until the safety needle and cap are secure.
Do not overtighten, as the needle hub may become damaged which could result in leakage of the product during injection. The safety shield may also be damaged if the safety needle and cap are screwed with too much force.
 |
Step 7
Move the safety shield away from the needle and towards the syringe.
Pull off the cap immediately prior to administration.
 |
Note: Should the needle hub appear to be damaged, or leak, do not use the product. If the needle hub is damaged or leakage is observed, use a new FENSOLVI carton.
 |
 |
 |
